Skip to content

Treatment and pathogenesis research of Banxia Baizhu Tianma decoction on borderline hypertension

Treatment and pathogenesis research of Banxia Baizhu Tianma decoction on borderline hypertension

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035796
Enrollment
Unknown
Registered
2020-08-17
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

borderline hypertension

Interventions

Sponsors

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with borderline hypertension; (2) With vertigo (or headache), consistent with the wind-phlegm syndrome; (3) Aged from 18 to 70 years; (4) Fully understand the study, sign the informed consent and ensure the compliance; (5) If the subject has been taking hypotensive related Traditional Chinese medicine or Western medicine, the drug should be stopped for 2 weeks before inclusion.

Exclusion criteria

Exclusion criteria: (1) Symptoms caused by Non-essential hypertension, diagnosed hypertension, nervous system disease, neurosis, cervical spondylosis, menopausal syndrome, etc.; (2) Patients with severe cardiopulmonary insufficiency, severe arrhythmia, immune system and other diseases; (3) Patients with allergic constitution or allergic to this test drug or patients with severe adverse reactions to this test drug; (4) Patients with tumors and cancers; (5) Manic, depression and other mental disorders; (6) Persons with a history of infectious diseases, such as tuberculosis, hepatitis B and HIV carriers. (7) Combined with poor controlled diseases such as diabetes, hyperlipidemia, respiratory infections, etc.; (8) A history of opioid analgesics, sedative and hypnotic drugs, and alcohol abuse; (9) Severe liver and kidney diseases or severe liver and kidney function impairment (ALT or AST are more than 1.5 times higher than the normal upper limit, and serum creatinine level is more than 1.5 times higher than the normal upper limit) (10) Patients with hematologic disorders, e.g. 1) hemoglobin <9g/dL, or hematocrit <30%; 2) White blood cell count <3.0x10^9/L; 3) Neutrophils count <1.2.0x10^9/L; 4) Platelet count <100x10^9/L, etc.; (11) Confirmed pregnant or suspected pregnant women, or having a pregnancy plan during the test.

Design outcomes

Primary

MeasureTime frame
ratio of blood pressure improvement;

Secondary

MeasureTime frame
metabolin;

Countries

China

Contacts

Public ContactLiu Ping
wangyiruen@163.com+86 18917763029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026